Contact PR

To use this feature, join Babbler easily !


Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up


Nice to see you again !

Press release

Ethypharm partners with Clever Leaves for medical cannabis products in Germany
timer minutes reading time minute reading time

Copy link
St-Cloud, France – March 17th, 2021 – Ethypharm has signed an exclusive licence agreement with Clever Leaves for the sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe.

Click to get original image size

This agreement expands the Ethypharm Group’s offering in its core therapeutic area of the Central Nervous System and confirms its commitment to support patients suffering with chronic pain.

Working with physicians and pharmacists to improve people’s lives is one of Ethypharm’s daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. Partnerships are part of Ethypharm’s DNA. We always look for the optimal partner in any country or region of the world. This collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the medical treatment care they need.” said Bertrand Deluard, CEO of Ethypharm.

Clever Leaves, a well recognised cannabis company, will manufacture and supply EU-GMP certified medical cannabis extracts sourced from their facilities in Colombia. The finished products will be marketed and distributed as an Ethypharm branded product portfolio in Germany by its local subsidiary in the 2nd half of 2021. The portfolio include high-CBD, high-THC, and balanced CBD-THC formulations aiming at the symptomatic treatment of neurological diseases as well as chronic pain in palliative settings.

This partnership with Ethypharm, an established European pharmaceutical company, advances our goal of providing market-leading medical cannabis products to patients. Clever Leaves’ focus on high-quality EU-GMP production and international supply chain has positioned us to develop, produce and ship products to endmarkets that will have significant impact on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves.

Germany is the second European market after France where the Ethypharm Group offers medical cannabis. Last January, Ethypharm was selected by the French health agency (National Agency for the Safety of Medicines and Health Products - ANSM) to provide medical cannabis products for the first ever French medical cannabis pilot program.

About the Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information visit and follow us on LinkedIn

Media Contacts Ethypharm


o Avril Ponnelle,, + 33 (0)1 41 12 17 20


o Markus Gladbach,, +49 157 71 44 60 98

o Christine Vogl-Kordick,, +49 172 86 50 982

inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here